News & Resources
July 19, 2016
Keystone Nano selected as a top scoring company by NCI investor review panel
Keystone Nano is pleased to announce that it has been selected for additional support from the National Cancer Institute of the National Institutes of Health. After a careful and competitive review by a National Cancer Institute (NCI) panel looking for leading investment opportunities among Small Business Innovation Research (SBIR) awardees, Keystone Nano was selected as a top scoring applicant and has been awarded support for business development.
“Keystone Nano is pleased to be selected as one of the leading NCI SBIR funded companies of 2016. We are grateful that NCI has recognized the value of our work and the approach we are taking. This selection further validates the commercial opportunities associated with our products and technologies”, remarked Mr. James Sharpe, Keystone Nano’s Vice President of Business Development.
Based in State College, PA, Keystone Nano is working at the interface between nanotechnology and the life sciences. The company is commercializing Ceramide NanoLiposome for the treatment of cancer, and is developing additional products using NanoJackets, non-toxic calcium phosphate nanoparticles that can be targeted to specific cell types and can deliver a wide range of materials from classical chemotherapeutics to siRNA and mRNA. The Company’s product pipeline is protected by a patent portfolio comprised of 11 patent families that has resulted in 14 issued patents and 8 pending applications to date.
March 17, 2016
KEYSTONE NANO SPONSORS GORDON RESEARCH CONFERENCE
Keystone Nano is pleased to announce that it has recently sponsored the Gordon Research Conference on Glycolipids and Sphingolipids - Homeostatis and Function in Health and Disease. The conference chair is Howard Riezman and the Vice Chair is Keystone Nano’s Chief Medical Officer Dr. Mark Kester. Dr. Kester is also the Director of the NanoSTAR Institute and a Professor of Pharmacology at the University of Virginia.
The conference was held in Lucca (Barga) from March 6 to 11 in Italy. Keystone Nano congratulates the organizers and participants in the conference and applauds their continuing research on sphingolipids.
Keystone Nano is currently working to commercialize a sphingolipid – Ceramide – as a novel cancer therapy. The Company’s product, Ceramide NanoLiposome, is a stable nanoliposome formulation of Ceramide that is expected to enter human clinical trials in mid-2016.
Based in State College, PA, Keystone Nano is working at the interface between nanotechnology and the life sciences. The company is commercializing Ceramide NanoLiposome and additional products using NanoJackets, calcium phosphate nanoparticles that may be targeted to specific cell types, for a variety of medical applications. The Company’s product pipeline is protected by a patent portfolio comprised of 11 patent families that has resulted in 14 issued patents and 8 pending applications to date.
For more information about Keystone Nano, our products and our technology, visit our website www.keystonenano.com, or contact Jeff Sirianni at PR@keystonenano.com.
March 15, 2016
KEYSTONE NANO SELECTED BY NATIONAL CANCER INSTITUTE TO PARTICIPATE IN BIO
Keystone Nano is pleased to announce that the National Cancer Institute (NCI) has selected the company to participate in BIO 2016, being held in San Francisco in June. Keystone Nano will participate in the bio-partnering program and the exhibit as a part of the NCI delegation of emerging cancer companies.
BIO’s International Convention has been a leading meeting worldwide for biotechnology and pharmaceutical companies for more than two decades. The meeting features tens of thousands of participants seeking to build cooperative business opportunities.
Keystone Nano is an emerging biopharmaceutical company developing three independent but interrelated nanotechnology therapeutic platforms for the treatment of cancer and infectious disease:
Ceramide Nanoliposome - a novel therapy that will begin human testing in August 2016 with a $2.0 million grant from the National Cancer Institute.
Photo Immuno Nano Therapy -- a non-toxic therapy for the treatment of cancer that combines immune up regulation and photo therapy utilizing NanoJackets. Keystone’s NanoJackets are biocompatible calcium phosphate nanoparticles that protect the active ingredient in serum and deliver it to the interior of the cell. They may be actively or passively targeted to specific cell types.
RNA-NanoJackets -- New therapies for the treatment of cancer and infectious disease using siRNA, mRNA and miRNA via NanoJackets.
At BIO, KN will be seeking partners interested in Ceramide NanoLiposome and the improved delivery of RNA as well as other anti-cancer compounds using NanoJackets.
Based in State College, PA, Keystone Nano is working at the interface between nanotechnology and the life sciences. The company is commercializing NanoJacket products and Ceramide NanoLiposome for a variety of medical applications. The Company’s product pipeline is protected by a patent portfolio comprised of 11 patent families that has resulted in 14 issued patents and 8 pending applications to date.
For more information about Keystone Nano, our products and our technology, visit our website www.keystonenano.com, or contact Jeff Siriani at PR@keystonenano.com.______________________________________________________________________________________________
November 2, 2015
Keystone Nano Promotes Dr. Mylisa Parette to Vice President of Research
Keystone Nano is pleased to announce the promotion of Dr. Mylisa Parette to Vice President of Research for the company. Dr. Parette was Keystone Nano’s first employee and began in 2005 and has made very significant contributions to the company over the course of the past ten years. Most notably she has served as Research Manager leading the company’s development of nanoparticles for the improved treatment of cancer. She has served as the Principal Investigator on five National Institute of Health awarded grants including the most recent grant supporting the start of clinical testing and has led our research team based in State College Pennsylvania and in Hershey Pennsylvania. Dr. Parette has also been instrumental in Keystone’s work with several important pharmaceutical and industrial partners coordinating the company’s research programs and developing custom nanoparticles for a range of solutions.
Keystone Nano is an emerging biopharmaceutical company developing three independent but interrelated nanotechnology therapeutic platforms for the treatment of cancer and infectious disease
1) Ceramide NanoLiposome -- a stable nanoliposomal formulation of ceramide, a known anti-cancer compoundnot previously deliverable, that is expected to enter Phase I/II with NCI funding in 2016
2) Photo Immuno Nano Therapy -- a non-toxic NanoJacket-ICG formulation with a dual mechanism of action, Photo Dynamic Therapy (PDT) and immunotherapy, for the treatment of cancer
3) siRNA-NanoJackets -- targeted siRNA therapeutics for the treatment of cancer and infectious disease. NanoJackets have also been shown to deliver mRNA and microRNA to targeted cells.
Based in State College, Keystone Nano is working at the interface between nanotechnology and the life sciences and has licensed intellectual property around nanoparticles from Penn State University and is further developing this technology. The company is working to commercialize NanoJacket products and NanoLiposomes for a variety of medical applications. The Company’s product pipeline is protected by a patent portfolio comprised of ten separate patent families that has resulted in 10 issued patents and 14 pending applications to date.
October 5, 2015
Keystone Nano Awarded $2 million Grant from National Cancer Institute to test new Cancer Therapy in Clinical Trial
Keystone Nano is pleased to announce that the National Cancer Institute (NCI) has awarded it a $2 million grant to support a Phase I clinical trial to determine the safety of Keystone’s Ceramide Nanoliposome (CNL) as a cancer therapy. The Small Business Investigational Research (SBIR) Grant is highly competitive and reflects a significant commitment from the NCI to support the development of this technology.
The grant supports a wide range of activities required to test the Ceramide Nanoliposome in humans at several leading cancer clinics. This first in human testing of the Company’s lead product will allow Keystone to learn more about the therapy’s effect in patients. The clinical trial is expected to begin in early 2016.
Dr. Mylisa Parette, Keystone Nano’s lead investigator on this project, remarked: “The CNL has a unique mechanism that selectively kills cancer cells while not affecting normal cells. It also delivers the drug in a NanoLiposome which provides further advantages. We are excited to take this next important step of determining the safety of this approach for cancer patients.” Edward A. Sausville, M.D., Ph.D., co-investigator on this project as well as Deputy Director and Associate Director for Clinical Research at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, noted: “CNL is a new strategy to deliver a drug ‘payload’ to cancer cells. It uses a “platform”---the Nanoliposome--- to deliver Ceramide, a regulator of cancer cell behavior, to cause cancer cell death. What is exciting is that many other different types of payloads could possibly use the Nanoliposome platform. CNL could pave the way for a new generation of drugs, each using the Nanoliposome platform to personalize a specific payload to a specific tumor type.” Mr. Jeff Davidson, Keystone Nano’s Chief Executive Officer, noted: “We are pleased to have NCI support to further develop and test this therapy. We look forward to determining if it can improve the treatments available for cancer patients.”
Testing is planned at three clinical centers: The University of Maryland Greenebaum Cancer Center, the University of Virginia and the Medical University of South Carolina. Ceramide Nanoliposomes have shown highly positive effects with no toxicity in multiple animal models of cancer including human liver cancer, breast cancer, melanoma, pancreatic cancer and leukemia.
Keystone Nano has been awarded several National Institute of Health (NIH) grants and a Pennsylvania Department of Health grant to develop nanoparticles for the treatment of cancer. Based in State College, PA, Keystone Nano is working at the interface between nanotechnology and the life sciences. Keystone Nano, which is building on technology licensed from Penn State University, is working to commercialize products for a variety of medical applications.
For more information about Keystone Nano, visit our website www.keystonenano.com, or contact Jeff Davidson.
For more information about the National Cancer Institute visit http://www.cancer.gov/about-nci.
For more information about the University of Maryland Greenebaum Cancer Center, visit www.umgcc.org .
As a highly contagious respiratory tract infection, Influenza causes annual epidemics that infect up to 10% of adults and 30% of children worldwide causing severe illness occurs in more than 3 million patients and an annual mortality of up to 500,000. In addition to seasonal influenza, several pandemics have been caused by highly virulent influenza strains, including the 1918 pandemic during which 50 million people died. Despite vaccination programs and therapies, influenza commonly develops resistance and remains widespread with substantial impacts on global health and productiveness.
Dr. Mylisa Parette of Keystone Nano and leader of this research notes: “The siRNA NanoJacket platform is widely applicable to many different diseases. We are excited to extend this technology to infectious diseases through this project with NIAID“. The company’s CEO, Mr. Jeff Davidson, observed that: “this contract provides an important opportunity to combat a serious illness in a very novel way, and we are excited about the prospects.”
Keystone is also pleased to be working with a new partner, IIT Research Institute (IITRI), based in Chicago, Illinois that has considerable expertise as a preclinical Contract Research Organization. Dr. David Boltz will lead IITRI’s team of scientists to test the efficacy and safety of the anti-influenza siRNA NanoJackets developed during this project.
Keystone Nano has been awarded several National Institute of Health (NIH) grants and a Pennsylvania Department of Health grant to build on Penn State University nanoparticle technology to developing nanoparticles for the treatment of cancer. Based in State College, Keystone Nano is working at the interface between nanotechnology and the life sciences and has licensed intellectual property around nanoparticles from Penn State University and is further developing this technology. The company is working to commercialize NanoJacket products and NanoLiposomes for a variety of medical applications.
For more information about Keystone Nano, visit our website www.keystonenano.com, or contact Jeff Davidson
For more information about IITRI, visit http://iitri.org, or contact Jessica Humphreys at firstname.lastname@example.org
For more information about the National Institutes of Allergy and Infectious Diseases visit http://www.niaid.nih.gov.
July 13, 2015
Keystone Nano's Latest Product Pipeline
June 9, 2015
Paper Published on Keystone Nano’s Ceramide Nanoliposome Program
Keystone Nano is pleased to announce the publication of a manuscript describing the preclinical development of the company’s lead product, the Ceramide Nanoliposome (CNL). This product is designed to more effectively treat cancer by providing selectively killing cancer cells without harming normal cells. The paper was published in June 2015 issue of Biological Chemistry and authored by Dr. Mylisa Parette, Keystone Nano’s Research Manager, Dr. Mark Kester, Keystone Nano’s Chief Medical Officer, Ms. Jocelyn Bassler, Keystone Nano Research Chemist, Dr. Carly Carter, Keystone Research Team Leader and Mr. Jeff Davidson, Keystone Nano’s CEO. Also contributing was Dr. Todd Fox of the University of Virginia.
Keystone Nano is currently compiling an Investigational New Drug filing on the Ceramide Nanoliposome for review by the US Food and Drug Administration. The company anticipates that the initial clinical trial will treat patients with a range of cancers. After this initial testing is complete, the company anticipates enrolling in clinical testing patients with Liver Cancer or other difficult to treat cancers.
Based in State College, Keystone Nano is working at the interface between nanotechnology and the life sciences and has licensed intellectual property around nanoparticles from Penn State University and is further developing this technology. The company is working to commercialize NanoJacket products and Nanoliposomes for a variety of medical applications.
For more information about Keystone Nano, visit our website keystonenano.com or follow us on twitter @keystonenano.
January 26, 2015
Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes
Keystone Nano is pleased to announce that Penn State has been awarded a US Patent (8,747,891) for a highly unique cancer therapy. Keystone Nano holds an exclusive license to this technology which builds on the work of Dr. Mark Kester of the University of Virginia. The inventing team includes: Mark Kester, Sriram Shanmugavelandy, and Todd Fox.
This patent describes an additional formulation of Ceramide Nano liposomes that can be loaded with a range of anti-cancer compounds to create combination therapies. These combinatorial therapies benefit from the therapeutic activity of both the Ceramide and the added anti-cancer compound. Simultaneous delivery of both therapeutics in a nano-liposome enhances the synergistic efficacy of the compounds by extending circulation and targeting the materials to tumors.
Keystone Nano has conducted extensive preclinical testing on the base Ceramide Nanoliposome formulation, which is described in an earlier patent for which Keystone Nano holds an exclusive license. A Pre IND package detailing this work was submitted to the US FDA and Keystone Nano anticipates moving the Ceramide Nanoliposome program into human clinical testing in the near term.
Based in State College, Keystone Nano is working at the interface between nanotechnology and the life sciences and has licensed intellectual property around nanoparticles from Penn State University and is further developing this technology. The company is working to commercialize NanoJacket products and Nanoliposomes for a variety of medical applications.
January 5, 2015
NIH Grant to Keystone Nano to Target Nanoparticles to Cancer Cells
KN is pleased to announce that it has been awarded a National Institute of Health (NIH) grant to further develop its nanoparticles for the treatment of cancer. The National Cancer Institute, a part of the NIH, has awarded a grant to Keystone Nano to further develop our siRNA nanoparticle technology.
Most current chemotherapeutics have are not selective to cancer cells and have dose-limiting toxicities that prevent optimal effects being obtained. Ribonucleic acid interference (RNAi) has the potential to be a safe, selective and personalized treatment approached for a variety of genetic-based diseases, including cancer. In particular, the design of small interfering RNA (siRNA) sequences to prevent the expression of cancer-fueling mutations provides a dramatic alternative to current therapeutic approaches. However, an effective delivery vehicle is required for systemic RNAi therapy to protect siRNA during circulation, concentrate siRNA at tumor sites and mediate cellular uptake as well as endosomal escape. This NIH funded project is designed to optimize a novel, combinatorial RNAi treatment for advanced breast cancer based on delivery by calcium phosphate nanoparticles, called NanoJackets. Building on the demonstrated in vivo efficacy of Keystone Nano’s siRNA NanoJackets, an active targeting ligand will be added and evaluated for improved biodistribution, cellular uptake and in vivo efficacy of siRNA NanoJackets for breast cancer therapy. If successful, the development of this targeted, combinatorial RNAi nano-therapeutic will provide a novel option for the personalized treatment of breast cancers that fail to respond to current therapies.
The project will be led by Dr. Mylisa Parette, Research Manager at Keystone Nano and Dr. Carly Carter, Research Team Leader at Keystone Nano. The project is supported by the company’s Chief Science Officer, Dr. James Adair, Chief Medical Officer, Dr. Mark Kester, and CEO, Mr. Jeff Davidson.
Based in State College, Keystone Nano is working at the interface between nanotechnology and the life sciences and has licensed intellectual property around nanoparticles from Penn State University. The company is working to commercialize NanoJacket products and Nanoliposomes for a variety of medical applications.
For more information about Keystone Nano, visit our website keystonenano.com.
Keystone Nano and Penn State College of Medicine Awarded $1 Million for the Development of Cancer Treatment Technology
The Pennsylvania Department of Health has awarded a $1 million PA CURE Grant to Keystone Nano and the Penn State College of Medicine to further develop an innovative, therapeutic drug delivery system called NanoJackets.
NanoJackets, which are stable, non-toxic particles, contain be loaded with small “interfering” ribonucleic acids (siRNA) that effectively deliver RNA to select cancer-causing mutated cells. NanoJackets effectively target and concentrate just at the tumor site, significantly diminishing the side effects for the patient. The goal of this project is to develop new therapies for cancer by preparing an Investigational New Drug (IND) application to the FDA for a novel product for the treatment of advanced cancers. Keystone Nano has been developing NanoJacket technology for the past six years.
Jeff Davidson, CEO of Keystone Nano, commented, “The American Cancer Society estimates that over 1.6 million patients will be diagnosed with cancer in 2012 and over 575,000 will die of the disease this year. Improving the effectiveness of cancer therapies by employing the use of nanotechnology can save lives and improve the patient’s quality of life both during and after therapy. We are seeking to move this promising technology promptly from the research bench to the clinic, and we appreciate the support of the Department of Health.”
Keystone Nano originally developed siRNA NanoJackets under a Phase I NCI SBIR contract and is currently optimizing formulations for preclinical testing. The company has also received significant support from Ben Franklin Technology Partners of Central and Northern Pennsylvania, the Pennsylvania Nanomaterials Commercialization Center, the Nanotechnology Institute, and from select corporate partners.
The project will be led by principal investigator Dr. Mark Kester, Passananti Professor of Pharmacology at the Penn State College of Medicine as well as Chief Medical Officer at Keystone Nano, Dr. Mylisa Parette, Research Manager at Keystone Nano and Dr. James Adair, Professor of Materials Science and Engineering at Penn State University as well as Chief Science Officer of Keystone Nano.
Based in State College, Keystone Nano is working at the interface between nanotechnology and the life sciences and has licensed intellectual property around nanoparticles from Penn State University. The company is working to commercialize NanoJacket products for a variety of medical applications.
June 14, 2011
Keystone Nano Receives Grant Award from the PA NanoMaterials Commercialization Center
The Pennsylvania NanoMaterials Commercialization Center has awarded Keystone Nano a grant to support the preclinical development of the Ceramide NanoLiposome.
The Ceramide NanoLiposome is being developed by Keystone Nano for evaluation as an improved therapeutic for Hepatocellular Carcinoma, also known as Liver Cancer. Liver Cancer is diagnosed in almost 750,000 people per year and is highly deadly with a 5 year survival rate of less than 2% when detected in the commonly diagnosed advanced state. The Ceramide NanoLiposome has demonstrated impressive efficacy in xenograft models of human liver cancer with no detectable toxicity. Keystone Nano plans to complete preclinical testing to enable regulatory review of the Ceramide NanoLiposome for initial clinical trials for Liver Cancer.
October 8, 2010
Keystone Nano Awarded a SBIR Contract from the National Cancer Institute
The National Cancer Institute (NCI) an Institute of the National Institutes of Health has awarded a Small Business Innovation Research (SBIR) contract to Keystone Nano to develop nanoparticles containing both diagnostic and therapeutic compounds to enhance the treatment of cancer. This is the second SBIR award from the NCI to support the development of Keystone Nano’s NanoJacket technology.
NanoJackets are small (30nm), colloidally stable, bioresorbable and can encapsulate various chemical compounds inside the nanoparticle. Keystone Nano has encapsulated a variety of compounds, including fluorescent molecules and chemotherapeutic drugs, within NanoJackets. Biological testing of prototypes indicates that NanoJackets both protect and enhance the effectiveness of encapsulated compounds by delivering them directly to desired locations, such as tumor sites. The nanoparticles developed with this contract will contain an imaging agent as well as a therapeutic compound. The encapsulation of both compounds within each NanoJacket will allow the simultaneous imaging and treatment of tumors, giving physicians the ability to monitor the effectiveness of the treatment in real time.
Jeff Davidson, CEO of Keystone Nano notes “Keystone Nano looks forward to further developing the diagnostic and therapeutic applications of NanoJackets with the support of the NCI”.
The American Cancer Society estimates that over 1.5 million patients will be diagnosed with cancer in 2010 and over 550,000 will die of the disease this year. Improving the effectiveness of cancer therapies by employing sensible nanotechnology can save lives and improve the patient’s quality of life both during and after therapy.
Dr. Mylisa Parette, author of the grant and principal investigator, will lead the research and development efforts associated with this project, supported by KN’s development team in State College and Hershey.
Keystone Nano is based in State College, Pennsylvania working at the interface between nanotechnology and the life sciences. Keystone Nano has licensed intellectual property around nanoparticles from Penn State University. The company is working to commercialize NanoJacket products for a variety of medical and industrial applications.
June 1, 2010
Keystone Nano opens its second laboratory to support for NanoJacket and NanoLiposome development.
Keystone Nano is announcing the opening of their second laboratory facility to support the development of NanoJacket and NanoLiposome products. The new laboratory, named Keystone Nano South, is located in the Hershey Center for Applied Research (HCAR) in Hummelstown, Pa and will provide biological testing for NanoJacket and NanoLiposome prototypes. Jeff Davidson, CEO of Keystone Nano, notes “We are excited to be expanding and opening our second laboratory. HCAR is an ideal home for Keystone Nano South, providing excellent access to resources at the Penn State College of Medicine.”
Jocelyn Bassler has been hired by Keystone Nano as a Biological Researcher to lead laboratory operations at Keystone Nano South.
September 28, 2009
Keystone Nano is awarded a NCI SBIR Phase I grant to support the development of targeted Doxorubicin NanoJackets for breast cancer treatment.
The National Cancer Institute has awarded Keystone Nano a Small Business Innovation Research (SBIR) grant to develop nanoparticle targeting as a way to improve the treatment of cancer. Dr. Mylisa Parette, Keystone’s Research Manager, observed: “We plan to use this grant to develop techniques to target very small nano packages of cancer drugs to cancerous tumors –the same way zip codes are used to direct mail on a journey.”
Dr. Mark Kester, the Passanatti Professor of Pharmacology at Hershey Medical Center and Keystone’s Chief Medical Officer emphasizes “Most current cancer therapies are untargeted and have little selectivity for cancerous tissue. As a result these drugs often cause side effects during treatment. We hope to dramatically decrease the negative impact of cancer therapy.”
The American Cancer Society estimated that over 1.4 million patients were diagnosed with cancer in 2008 and many of those were treated with chemotherapeutics. Improving therapies by employing sensible nanotechnology can save lives and improve the patient’s quality of life both during and after therapy.
Keystone Nano’s NanoJacket delivery system is distinct from other nano approaches in that NanoJackets are made of biologically compatible materials (calcium and phosphate), and are exceptionally small, versatile and protective.
Dr. Parette, principal investigator and author of the grant, will lead the research and development effort associated with this project.
Keystone Nano is based in State College, Pennsylvania working at the interface between nanotechnology and the life sciences. Keystone Nano has licensed intellectual property around nanoparticles from Penn State University. The company is working to commercialize NanoJacketed products – or nano-enhanced products.
March 5, 2009
Keystone Nano is named “Outstanding Technology Company of the Year” at the Center for Business and Industry Centre County awards gala.
July 7, 2008
Keystone Nano is awarded a NanoApplications Fund grant from the Nanotechnology Institute of Pennsylvania
Keystone Nano has been awarded a Nano Applications Fund (NAF) grant from the Nanotechnology Institute of Pennsylvania to support the development of chemotherapeutic NanoJackets for improved breast cancer treatment. This project involves initial prototype development to encapsulate an FDA-approved chemotherapeutic drug within NanoJackets. Dr. Mylisa Parette, principal investigator for this project, comments “We would like to thank the Nanotechnology Institute for their support and hope to bring NanoJacketed chemotherapeutics to the market for improved breast cancer treatment.”
July 25, 2007
Keystone Nano and Nalco Announce Joint Nanotechnology Development Venture
Keystone Nano, a nanotechnology development company in State College and Nalco Company (NYSE:NLC), the leading global provider of integrated water treatment and process improvement services, chemicals and equipment programs for industrial and institutional applications, announced the formation of a joint venture company, NanoSpecialties, LLC. The new company will create new products with nano-features for industrial markets.
The venture will conduct research and development of nanotechnology that allows for more precise application of various Nalco water and process treatments.
Keystone Nano has licensed two Penn State University patent applications that protect the creation of NanoJackets™, particles with a diameter of about 40 nanometers. The technology was developed through collaborative efforts between Professor James Adair’s research group in Penn State’s Materials Research Institute and Passanati Distinguished Professor Mark Kester’s research group at the Hershey Medical Center. The NanoJackets can be customized to contain specialty chemicals within an exceptionally small, effective, and safe delivery system.
These customized NanoJackets will allow:
Improved time-release of the treatment agents
Precise targeting of the treatments at the molecular level to focus the effects, and
More stable treatment agents within an engineered nanoscale package
Jeff Davidson, Keystone Nano’s CEO notes that “Combining the development and marketing strengths of Nalco with Keystone’s nanotechnology capabilities allows us to create some very exciting new products for industrial customers. We are looking forward to commercializing a range of NanoJacket applications with Nalco.”
“This effort with Keystone Nano will develop cutting-edge means to better deliver Nalco’s world-class chemistries in a variety of applications. Using nanotechnology will further improve the effectiveness of our treatment programs while reducing the amount of chemical used to achieve those results,” said Nalco Chairman and Chief Executive Officer Dr. William H. Joyce.
Keystone Nano is currently using NanoJackets to create new medical therapeutics with decreased toxicity and dosage levels. The company is also creating new research and diagnostic imaging applications featuring stable, versatile nano-imaging products.
Nalco has a long history of work in nanotechnology dating to the 1950s and the development of colloidal silicas. Recent innovations such as Core Shell® polymers, modified at the molecular level for use in wastewater treatment and as process aids in papermaking, petroleum refining, mining and food and beverage processing, continue this commitment to innovation.
Nanotechnology is the manipulation of materials at the molecular level to achieve specific results. The term derives from nanometer, a metric unit of measure equal to one billionth of a meter
About Keystone Nano
Keystone Nano is a development stage company based in State College, Pennsylvania working at the interface between nanotechnology and the life sciences. More information is available on the company at www.keystonenano.com or by calling 814-466-5080.
Nalco serves more than 70,000 customer locations representing a broad range of end markets. It has established a global presence with more than 11,000 employees operating in 130 countries supported by a comprehensive network of manufacturing facilities, sales offices and research centers. In 2006, Nalco achieved sales of more than $3.6 billion. For more information visit www.nalco.com.
This news release includes forward-looking statements, reflecting current analysis and expectations, based on what are believed to be reasonable assumptions. Forward-looking statements may involve known and unknown risks, uncertainties and other factors, which may cause the actual results to differ materially from those projected, stated or implied, depending on many factors, including, without limitation: ability to generate cash, ability to raise capital, ability to refinance, the result of the pursuit of strategic alternatives, ability to execute work process redesign and reduce costs, ability to execute price increases, business climate, business performance, economic and competitive uncertainties, higher manufacturing costs, reduced level of customer orders, changes in strategies, risks in developing new products and technologies, environmental and safety regulations and clean-up costs, foreign exchange rates, the impact of changes in the regulation or value of pension fund assets and liabilities, changes in generally accepted accounting principles, adverse legal and regulatory developments, including increases in the number or financial exposures of claims, lawsuits, settlements or judgments, or the inability to eliminate or reduce such financial exposures by collecting indemnity payments from insurers, the impact of increased accruals and reserves for such exposures, weather-related factors, and adverse changes in economic and political climates around the world, including terrorism and international hostilities, and other risk factors identified by the Company. Accordingly, there can be no assurance that the Company will meet future results, performance or achievements expressed or implied by such forward-looking statements. This paragraph is included to provide safe harbor for forward-looking statements, which are not generally required to be publicly revised as circumstances change, and which the Company does not intend to update.
November 2006 Yellow Cakes
Connecting the Dots Keystone Nano Targets Cancer Treatment by Judith Sen
What do you do if you have a great technology in search of a product? If you are Jeff Davidson, CEO of Keystone Nano in Boalsburg , Pennsylvania , you head off to BIO. BIO is an international biotechnology convention organized by the Biotechnology Industry Organization. “I attended the last two conventions,” said Davidson, “BIO is a great place for finding partners.” Keystone Nano has entered into partnerships with two corporate partners and is also working with three other companies interested in developing applications for the company's Molecular Dot technology...
Keystone Nano Named International Winner of The Second Annual International Nanotechnology Business Idea Competition
Company is developing Molecular Dots for Improved Disease Imaging and Drug Delivery
CLEVELAND, October 21, 2005 - Keystone Nano won the International Award of $75,000 in the second annual International and North Coast Nanotechnology Business Idea Competitions held on the campus of Case Western Reserve University. http://www.tiime.case.edu/nano/ A panel of judges featuring representatives of venture capital firms, corporations and nanotechnology researchers selected Keystone Nano as the International winner.
Keystone Nano is building its company around technology developed at Penn State University and at the Hershey Medical Center. "We'll leverage this award to speed the development of the company", said Jeff Davidson, chief executive officer of Keystone Nano. "The science is outstanding - as it allows the creation of trillions of distinct tiny drug containing Molecular Dots - now we want to build an outstanding business that uses these dots to improve human health."
"Winning the International Nanotechnology Business Idea Competition provides important validation for its technology and business team," said Mark Kester, chief medical officer for Keystone Nano. Dr. Kester is also a professor at the Penn State College of Medicine in Hershey, Pennsylvania. "We've got some momentum now and we're going to take advantage of it," Dr. Kester said.
The company has developed Molecular Dots that are 10 nanometers to 80 nanometers particles that can deliver either therapeutic drugs or imaging solutions inside a patient's body. The Molecular Dots are so tiny that they don't prompt a response from the body's immune system and can work more effectively than other internal drug delivery or imaging systems.
In the imaging area the company is working to use these MDs to more precisely image cancerous tumors earlier in the cancer development process. The goal of this early imaging is to identify cancers when they are smaller and before they have spread to other organs. Identifying cancer earlier helps improve treatment options. If Keystone Nano's imaging is successful it should result in fewer cancer deaths and more modest surgical or drug therapy interventions.
Keystone Nano's molecular dots are designed to improve the delivery of drugs that are not water soluble, or that have physical characteristics that make them difficult to deliver. These reluctant drugs can be dispatched in a miniaturized trucking force of 1,000 trillion Molecular Dots that will deliver the drugs to remote regions of the human body. The drugs delivered will improve drug therapy for patients being treated for a variety of cancers or cardiovascular diseases.
Organizers of the Nanotechnology competition include three Case Western Reserve University programs and NorTech's Nano-Network. Sponsors include ASM International, Nanofilm, Ferro Corp., Case, Forest City Enterprises, The Partnerships for Innovation Program of the National Science Foundation and the Joseph P. & Nancy F. Keithley Foundation.
Last year's top winner of the competition, QD Vision of Watertown, Mass., recently raised at least $6 million in venture capital in a venture round financed by Highland Capital Partners, North Bridge Venture Partners, and OI Ventures. Gary Wnek, co-director of TiME at Case Western Reserve University remarked "I wouldn't be surprised at all if a few of our finalists today are able to attract venture capital in the near future."
Recent Media Coverage
October 25, 2005 - Centre Daily Times - Company wins big prize for small work
October 22, 2005 - Nanotechnology Now - Nanotechnology Business Idea Competition Winners Announced
October 21, 2005 - NANOVIP - $150,000 in Nano Competitions Awarded
October 21, 2005 - Crain's Cleveland Business - Big Prize for Small Work
October 21, 2005 - Case Western - Nanotechnology Business Idea Competition Winners Announced